Why Two High-Profile Heart Drugs Failed and What It Means for Future Therapies
Two major heart-disease drug trials backed by Novo Nordisk and Novartis did not meet expectations, prompting questions about the next wave of cardiovascular medicines.
Large-scale clinical studies of promising heart drugs from Novo Nordisk and Novartis fell short, despite billions invested. Cardiologist and biotech founder Ethan Weiss explained the unexpected outcomes and their implications for future drug development. The discussion also covered recent FDA approvals and upcoming cancer treatments from Merck and Moderna.
Why it matters
The failures reveal challenges in heart-drug development, affecting future treatments and industry investment.
In this story
heart diseaseclinical trial failurecardiovascular drugspharma investmentEthan WeissNovo NordiskNovartisFDA approvalsMerckModerna
